Synthesis of epoxyisoprostanes: Effects in reducing secretion of pro-inflammatory cytokines IL-6 and IL-12

Angewandte Chemie - International Edition

Volumn 52, Issue 20, 2013, Pages 5382-5385

  Egger, Julian ^a   Bretscher, Peter ^a   Freigang, Stefan ^a   Kopf, Manfred ^a   Carreira, Erick M ^a  

^a ETH ZURICH   (Switzerland)

Author keywords

anti inflammatory agents; C H insertion; isoprostanoids; natural products; oxidized phospholipids

Indexed keywords

ANTI-INFLAMMATORY AGENTS; C-H INSERTION; ISOPROSTANOIDS; NATURAL PRODUCTS; OXIDIZED PHOSPHOLIPIDS;

BIOACTIVITY; PHOSPHOLIPIDS;

PHYSIOLOGY;

ANTIINFLAMMATORY AGENT; EPOXIDE; INTERLEUKIN 12; INTERLEUKIN 6; ISOPROSTANE DERIVATIVE; PHOSPHATIDYLCHOLINE;

ANIMAL; ARTICLE; CELL CULTURE; CHEMICAL STRUCTURE; CHEMISTRY; DENDRITIC CELL; DRUG ANTAGONISM; DRUG EFFECT; IMMUNOLOGY; SECRETION (PROCESS); SYNTHESIS;

ANIMALS; ANTI-INFLAMMATORY AGENTS; CELLS, CULTURED; DENDRITIC CELLS; EPOXY COMPOUNDS; INTERLEUKIN-12; INTERLEUKIN-6; ISOPROSTANES; MOLECULAR STRUCTURE; PHOSPHATIDYLCHOLINES;

EID: 84877275641     PISSN: 14337851     EISSN: 15213773     Source Type: Journal    
DOI: 10.1002/anie.201300739     Document Type: Article

References (53)

1. N. Leitinger, et al., J. Immunol. 2005, 175, 501-508
2. for a comprehensive review on oxidized phospholipids, see:, U. Jahn, J.-M. Galano, T. Durand, Angew. Chem. 2008, 120, 5978-6041
3. Angew. Chem. Int. Ed. 2008, 47, 5894-5955
4. for the first discovery of isoprostanes in humans, see:, J. D. Morrow, K. E. Hill, R. F. Burk, T. M. Nammour, K. F. Bodr, L. J. Roberts II, Proc. Natl. Acad. Sci. USA 1990, 87, 9383-9387
5. for an introduction to the nomenclature of the isoprostanes, see:, D. F. Taber, J. D. Morrow, R. Jackson Roberts II, Prostaglandins 1997, 53, 63-67.
6. N. Leitinger, Subcell. Biochem. 2008, 49, 325-350
7. I. Levitan, S. Volkov, P. V. Subbaiah, Antioxid. Redox Signaling 2010, 13, 39-75.
8. J. C. Ullery, L. J. Marnett, Biochim. Biophys. Acta Biomembr. 2012, 1818, 2424-2435.
9. For a review see:, N. Leitinger, Mol. Nutr. Food Res. 2005, 49, 1063-1071
10. M. Navab, et al., J. Lipid Res. 2004, 45, 993-1007
11. J. A. Berliner, N. Leitinger, S. Tsimikas, J. Lipid Res. 2009, 50, S 207 -S 212
12. J. A. Berliner, A. D. Watson, N. Engl. J. Med. 2005, 353, 8-11
13. N. Leitinger, et al., Arterioscler. Thromb. Vasc. Biol. 2005, 25, 633-638
14. A. D. Watson, N. Leitinger, M. Navab, K. F. Faull, S. Horkko, J. L. Witztum, W. Palinski, D. Schwencke, R. G. Salomon, W. Sha, G. Subbanagounder, A. M. Fogelman, J. A. Berliner, J. Biol. Chem. 1997, 272, 13597-13607
15. A. D. Watson, G. Subbanagounder, D. S. Welsbie, K. F. Faull, N. Navab, M. E. Jung, A. Fogelman, J. A. Berliner, J. Biol. Chem. 1999, 274, 24787-24798.
16. K. G. Birukov, V. N. Bochkov, A. A. Birukova, K. Kawkitinarong, A. Rios, A. Leitner, A. D. Verin, G. M. Bokoch, N. Leitinger, J. G. N. Garcia, Circ. Res. 2004, 95, 892-901
17. G. Subbanagounder, J. W. Wong, H. Lee, K. F. Faull, E. Miller, J. L. Witztum, J. A. Berliner, J. Biol. Chem. 2002, 277, 7271-7281.
18. Besides human-derived oxidized phospholipids our group is also interested in oxidized lipids from marine sources and their effect on humans; see:, C. Nilewski, R. W. Geisser, E. M. Carreira, Nature 2009, 457, 573-576
19. C. Nilewski, R. W. Geisser, M.-O. Ebert, E. M. Carreira, J. Am. Chem. Soc. 2009, 131, 15866-15876
20. C. Nilewski, N. R. Deprez, T. C. Fessard, D. B. Li, R. W. Geisser, E. M. Carreira, Angew. Chem. 2011, 123, 8087-8091
21. Angew. Chem. Int. Ed. 2011, 50, 7940-7943
22. C. Nilewski, E. M. Carreira, Eur. J. Org. Chem. 2012, 1685-1698.
23. V. N. Bochkov, O. V. Oskolkova, K. G. Birukov, A.-L. Levonen, C. J. Binder, J. Stöckl, Antioxid. Redox Signaling 2010, 12, 1009-1059.
24. M. E. Jung, J. A. Berliner, L. Koroniak, B. G. Gugiu, A. D. Watson, Org. Lett. 2008, 10, 4207-4209
25. M. E. Jung, J. A. Berliner, D. Angst, D. Yue, L. Koroniak, A. D. Watson, R. Li, Org. Lett. 2005, 7, 3933-3935.
26. H. P. Acharya, Y. Kobayashi, Angew. Chem. 2005, 117, 3547-3550
27. Angew. Chem. Int. Ed. 2005, 44, 3481-3484
28. H. P. Acharya, Y. Kobayashi, Tetrahedron Lett. 2005, 46, 8435-8438
29. for an acetylene analogue, see:, H. P. Acharya, K. Miyoshi, Y. Kobayashi, Org. Lett. 2007, 9, 3535-3538.
30. For a full-chain approach to isoprostanes by means of intramolecular cyclopropanation, see:, D. F. Taber, R. S. Hoerrner, R. J. Herr, D. M. Gleave, K. Kanai, R. Pina, Q. Jiang, M. Xu, Chem. Phys. Lipids 2004, 128, 57-67.
31. For large-scale preparations the less expensive (Z)-decenol was used and oxidized to the aldehyde under Swern conditions according to:, R. A. Fernandes, P. Kattanguru, Tetrahedron: Asymmetry 2011, 22, 1930-1935.
32. C. Zhu, X. Shen, S. G. Nelson, J. Am. Chem. Soc. 2004, 126, 5352-5353.
33. For the formal acetate aldol reaction Nelson developed a chiral Lewis acid catalyzed cycloaddition; however, the alkaloid-catalyzed version worked very well in our case. For the Lewis acid catalyzed version, see:, S. G. Nelson, C. Zhu, X. Shen, J. Am. Chem. Soc. 2004, 126, 14-15.
34. T. Yakura, S. Yamada, A. Ueki, M. Ikeda, Synlett 1997, 185-186
35. T. Yakura, S. Yamada, Y. Kunimune, A. Ueki, M. Ikeda, J. Chem. Soc. Perkin Trans. 1 1997, 3643-3649
36. T. Yakura, S. Yamada, M. Azuma, A. Ueki, M. Ikeda, Synthesis 1998, 973-974
37. for later work on a Rh-catalyzed diastereoselective cyclization, see:, D. F. Taber, J. H. Green, W. Zhang, R. Song, J. Org. Chem. 2000, 65, 5436-5439.
38. M. Marigo, J. Franzén, T. B. Poulsen, W. Zhuang, K. A. Jørgensen, J. Am. Chem. Soc. 2005, 127, 6964-6965.
39. Also Sharpless oxidation of the corresponding alcohol results in relatively low yields:, B. E. Rossiter, T. Katsuki, K. B. Sharpless, J. Am. Chem. Soc. 1981, 103, 464-465.
40. M. Suzuki, M. Mori, T. Niwa, R. Hirata, K. Furuta, T. Ishikawa, R. Noyori, J. Am. Chem. Soc. 1997, 119, 2376-2385.
41. M. Miyashita, T. Suzuki, A. Yoshikoshi, Tetrahedron Lett. 1989, 30, 1819-1820
42. M. Miyashita, T. Suzuki, M. Hoshino, A. Yoshikoshi, Tetrahedron 1997, 53, 12469-12486.
43. J. Cossy, A. Bouzide, S. Ibhi, P. Aclinou, Tetrahedron 1991, 47, 7775-7782
44. H. E. Ensley, E. J. Corey, J. Org. Chem. 1973, 38, 3187-3190
45. C. Hardouin, F. Chevallier, B. Rousseau, E. Doris, J. Org. Chem. 2001, 66, 1046-1048
46. J. A. R. Salvador, A. J. L. Leitão, M. L. Sá e Melo, J. R. Hanson, Tetrahedron Lett. 2005, 46, 1067-1070
47. R. Jankowska, G. L. Mhehe, H.-J. Liu, Chem. Commun. 1999, 1581-1582
48. H. Paulsen, K. Eberstein, W. Koebernick, Tetrahedron Lett. 1974, 15, 4377-4380
49. F. Zhang, E. D. Moher, T. Y. Zhang, Tetrahedron Lett. 2007, 48, 3277-3279.
50. 2, see:, M. Szostak, M. Spain, D. J. Procter, J. Org. Chem. 2012, 77, 3049-3059
51. 2, see:, G. A. Molander, G. Hahn, J. Org. Chem. 1986, 51, 2596-2599.
52. A. M. Barrie III, S. E. Plevy, Clin. Appl. Immunol. Rev. 2005, 5, 225-240
53. T. Kishimoto, Int. Immunol. 2010, 22, 347-352.